{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:00:21Z","timestamp":1784786421129,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"DOI":"10.7759\/cureus.81285","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T17:53:09Z","timestamp":1743097989000},"source":"Crossref","is-referenced-by-count":2,"title":["A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Avelumab"],"prefix":"10.7759","author":[{"given":"Lu","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Encun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1551671","article-title":"Product review: avelumab, an anti-PD-L1 antibody","volume":"15","author":"Collins JM","year":"2019","unstructured":"Collins JM, Gulley JL. Product review: avelumab, an anti-PD-L1 antibody. Hum Vaccin Immunother. 2019, 15:891-908. 10.1080\/21645515.2018.1551671","journal-title":"Hum Vaccin Immunother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Flaig TW","year":"2020","unstructured":"Flaig TW, Spiess PE, Agarwal N, et al.. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020, 18:329-54. 10.6004\/jnccn.2020.0011","journal-title":"J Natl Compr Canc Netw"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:394-424. 10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein JP","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, et al.. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001, 19:666-75. 10.1200\/JCO.2001.19.3.666","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102050","article-title":"Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice","volume":"8","author":"Grivas P","year":"2023","unstructured":"Grivas P, Grande E, Davis ID, et al.. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice. ESMO Open. 2023, 8:102050. 10.1016\/j.esmoop.2023.102050","journal-title":"ESMO Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103464","article-title":"Efficacy and safety profile of avelumab monotherapy","volume":"166","author":"Zhao B","year":"2021","unstructured":"Zhao B, Gao M, Zhao H, Zhao J, Shen X. Efficacy and safety profile of avelumab monotherapy. Crit Rev Oncol Hematol. 2021, 166:103464. 10.1016\/j.critrevonc.2021.103464","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda T","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013, 10:796-803. 10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman KJ","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004, 13:519-23. 10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans SJ","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001, 10:483-6. 10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate A","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998, 54:315-21. 10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020242","article-title":"Safety surveillance of pneumococcal vaccine using three algorithms: disproportionality methods, empirical Bayes geometric mean, and tree-based scan statistic","volume":"8","author":"Lee H","year":"2020","unstructured":"Lee H, Kim JH, Choe YJ, Shin JY. Safety surveillance of pneumococcal vaccine using three algorithms: disproportionality methods, empirical Bayes geometric mean, and tree-based scan statistic. Vaccines (Basel). 2020, 8:242. 10.3390\/vaccines8020242","journal-title":"Vaccines (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.030","article-title":"Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 phase 3 trial","volume":"84","author":"Grivas P","year":"2023","unstructured":"Grivas P, Park SH, Voog E, et al.. Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 phase 3 trial. Eur Urol. 2023, 84:95-108. 10.1016\/j.eururo.2023.03.030","journal-title":"Eur Urol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2028621","article-title":"Avelumab in locally advanced or metastatic urothelial carcinoma","volume":"22","author":"Jackson-Spence F","year":"2022","unstructured":"Jackson-Spence F, Szabados B, Toms C, Yang YH, Sng C, Powles T. Avelumab in locally advanced or metastatic urothelial carcinoma. Expert Rev Anticancer Ther. 2022, 22:135-40. 10.1080\/14737140.2022.2028621","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.27","article-title":"A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses","volume":"5","author":"Grenga I","year":"2016","unstructured":"Grenga I, Donahue RN, Lepone LM, Richards J, Schlom J. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology. 2016, 5:e83. 10.1038\/cti.2016.27","journal-title":"Clin Transl Immunology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen EM","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, et al.. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015, 350:207-11. 10.1126\/science.aad0095","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte MJ","year":"2007","unstructured":"Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007, 27:111-22. 10.1016\/j.immuni.2007.05.016","journal-title":"Immunity"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown JA","year":"2003","unstructured":"Brown JA, Dorfman DM, Ma FR, et al.. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003, 170:1257-66. 10.4049\/jimmunol.170.3.1257","journal-title":"J Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10262","article-title":"Mechanism of FGF receptor dimerization and activation","volume":"7","author":"Sarabipour S","year":"2016","unstructured":"Sarabipour S, Hristova K. Mechanism of FGF receptor dimerization and activation. Nat Commun. 2016, 7:10262. 10.1038\/ncomms10262","journal-title":"Nat Commun"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/342654-a-real-world-pharmacovigilance-study-of-fda-adverse-event-reporting-system-events-for-avelumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T17:53:11Z","timestamp":1743097991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/342654-a-real-world-pharmacovigilance-study-of-fda-adverse-event-reporting-system-events-for-avelumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.81285","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,27]]}}}